Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 2201–2250 of 18397
on February 26, 2025, the Company appointed Mark Matthews as Chief Financial Officer of the Company, effective as of the Resignation.
appointed Lance T. Loeffler, 48, as senior vice president and chief financial officer of the Company, effective April 1, 2025.
notified the Company of her decision to resign to pursue other opportunities, effective as of March 14, 2025.
On February 28, 2025, the Company announced that the Board of Directors has appointed Ronald J. Fior as the Company’s Interim Chief Financial Officer, as well as the Company’s principal financial officer and principal accounting officer for purposes of the Securities Exchange Act of 1934, as amended, in each case, effective March 15, 2025
On February 24, 2025, Franco Valle resigned as the Chief Financial Officer (principal financial officer and principal accounting officer) of Biomea Fusion, Inc. (the “Company”), effective March 7, 2025.
Robert P. Mundy, Packaging Corporation of America’s (“PCA”) Executive Vice President and Chief Financial Officer, and PCA’s principal financial officer and principal accounting officer, notified PCA that he will step down as Chief Financial Officer on May 1, 2025.
Kent A. Pflederer, age 54, PCA’s Senior Vice President, General Counsel and Secretary, will become PCA’s Executive Vice President and Chief Financial Officer on May 1, 2025
Effective March 1, 2025, Gerald Quirk will cease to serve as Chief Executive Officer and President of the Company.
In connection with the appointment of Ms. Wolfe Herd, the Company’s Founder and Executive Chair of the Board, to the role of the Company’s Chief Executive Officer, effective as of March 17, 2025
On February 24, 2025, Dr. Ralph Schiess resigned from his positions as the Interim Chief Executive Officer and Chief Science Officer of Onconetix, Inc. (the “Company”), effective immediately
On February 28, 2025, the Board of Directors of Green Plains Inc. (the “Company”) announced by press release the departure of Todd Becker as President and Chief Executive Officer and member of the Board of Directors (the “Board”) of the Company, effective March 1, 2025.
The Board designated Ms. Mapes as interim principal executive officer, effective as of March 1, 2025, for purposes of the rules and regulations of the Securities Exchange Commission.
Mr. Glazer will cease to be the principal accounting officer of the Company, but will continue his role as Chief Financial Officer and Treasurer, following the Effective Time.
Patrick Huvane, the Vice President of Corporate Development, will become Interim CEO.
On February 28, 2025, Associated Capital Group, Inc. (the “Company”) announced that Douglas R. Jamieson will be retiring as its Chief Executive Officer and President effective March 17, 2025, and will continue in his role as a Director of the Company.
Peter Beetham, the Company’s President and Chief Operating Officer, was appointed as Interim Chief Executive Officer
On February 24, 2025, Rory Riggs resigned as the Chief Executive Officer of Cibus, Inc.
Until a successor is appointed by the Company, Carrie Osicka, the Company’s Chief Financial Officer, has assumed the responsibilities of the Company’s principal accounting officer, effective as of February 27, 2025.
On February 25, 2025, the Board appointed Caitlin Schaefer as Chief Accounting Officer and will serve as the Company’s interim principal financial officer and principal accounting officer, effective March 1, 2025 (the “Effective Date”).
As previously reported, on February 17, 2025, Anthony Querciagrossa informed the Board of Directors (the “Board”) of Pinstripes Holdings, Inc. (the “Company”) of his resignation as Chief Financial Officer of the Company, effective February 28, 2025.
who on February 24, 2025 informed the Company that he will retire as Executive Vice President and Chief Financial Officer of the Company, effective April 1, 2025.
the Company’s Board of Directors appointed John R. Deren, 57, who has served as the Company’s Corporate Vice President and Chief Accounting Officer since May 2017, to serve as Executive Vice President and Chief Financial Officer of the Company, effective April 2, 2025.
the Board unanimously appointed President and Director Mr. Robert S. Lowenthal (48) to serve as CEO of the Company and Opco, effective simultaneously with Mr. Albert Lowenthal’s transition.
On February 24, 2025, Ms. Sherry Aulin notified the Company of her decision to resign as Chief Financial Officer, effective June 30, 2025, for personal reasons.
The Company previously announced that Richard Booth, the Company’s current CFO, would be departing the Company effective June 1, 2025.
On February 24, 2025, the Board of Directors (the “Board”) of the Company appointed Casey Heller to the position of Chief Financial Officer (“CFO”) effective June 2, 2025.
promoted David Bourdon to serve as the Company’s Chief Executive Officer effective as of March 3, 2025
the Board of Directors also appointed Ryan McGroarty as the Company’s Chief Financial Officer and Treasurer, effective as of March 17, 2025
On February 27, 2025, Moelis & Company (the “Company”) announced the appointment of Christopher Callesano to Chief Financial Officer effective March 31, 2025.
Mr. Simon provided notice of his resignation on February 25, 2025 and will be leaving the Company at the end of May.
On February 25, 2025, Ignacio Alvarez announced his retirement as Chief Executive Officer (“CEO”) of Popular, Inc. (“Popular” or the “Corporation”), effective June 30, 2025 (the “Retirement Date”).
Each of Andrew Spaventa, the Company’s Chief Executive Officer and Chair of the Company’s Board, Eli Glezer, Ph.D., the Company’s Chief Scientific Officer and Dalen Meeter, the Company’s Chief Financial Officer resigned from the Company, effective as of immediately prior to the Effective Time.
Each of Andrew Spaventa, the Company’s Chief Executive Officer and Chair of the Company’s Board, Eli Glezer, Ph.D., the Company’s Chief Scientific Officer and Dalen Meeter, the Company’s Chief Financial Officer resigned from the Company, effective as of immediately prior to the Effective Time.
Immediately following the Effective Time, Joshua Stahl was appointed as the Company’s Chief Executive Officer and Jason Myers was appointed as the Company’s President.
Ms. Spofford has agreed to extend her retirement date to April 30, 2025
On February 27, 2025, J.Jill, Inc. (the “Company”) announced that it has appointed Mary Ellen Coyne to serve as the Company’s Chief Executive Officer and President to succeed the Company’s current Chief Executive Officer and President, Claire Spofford, following Ms. Spofford’s previously disclosed decision to retire.
appointed Don Kim as Chief Financial Officer of the Company, effective as of March 27, 2025.
accepted the resignation of Thomas Hess as Chief Financial Officer of the Company, effective as of March 26, 2025.
On February 24, 2025, Michael D. Cahill, VWF Bancorp Inc.'s (the "Company") President and Chief Executive Officer, a member of the Board of Directors of the Company, the Company's subsidiary GreenWay Bank's (the "Bank") President and Chief Executive Officer, and a member of the Board of Directors of the Bank, notified the Company and the Bank that he will retire from the Company and the Bank, at the end of the current term of his employment agreement, effective December 31, 2025.
On February 24, 2025, Steven Tuch, Executive Vice President and Chief Financial Officer of vTv Therapeutics Inc. (the "Company"), informed the Company of his intention to resign from his position effective March 21, 2025.
On February 25, 2025, the Company’s Board of Directors appointed Navam Welihinda as Elastic’s Chief Financial Officer, effective as of February 28, 2025, to succeed Eric Prengel.
Eric Prengel, who has served as the Interim Chief Financial Officer of the Company since December 14, 2024, will cease to serve in this role on February 28, 2025 upon the effectiveness on that date of the appointment of Navam Welihinda as the Company’s Chief Financial Officer
On February 23, 2025, Innovation1 Biotech Inc. (the “Company”) appointed Samuel Knipper to serve as chief financial officer of the Company.
David Lazar, the Company’s interim Chief Executive Officer, interim principal financial officer, interim principal accounting officer, and Secretary, provided notice of his resignation as Chief Executive Officer and Secretary of the Company effective February 26, 2025.
the Board appointed Datuk Dr. Doris Wong Sing Ee, as Chief Executive Officer and, in such role, she will serve as the Company’s principal executive officer.
Paul M. Shoukry simultaneously assumed the role of CEO
the Board appointed Niccolo de Masi to serve as President and Chief Executive Officer of the Company, succeeding Peter Chapman effective as of February 26, 2025
the Board appointed Stephen C. Farrell to succeed Thomas G. Frinzi as President and Chief Executive Officer, effective February 26, 2025
Effective as the Effective Date, Mr. Frinzi has agreed to step down at the request of the Board from his positions as President and Chief Executive Officer, and he will cease to serve as a member of the Board of Directors and Board Chair and all other positions with the Company and its subsidiaries.
to succeed Madhu Ranganathan.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.